Kato A, Miyoshi N, Ohtsuru T, Sakai D, et al. A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202). Anticancer Res 2022;42:1859-1865.
PMID: 35347004